News

Hosted on MSN3mon
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...
Nasdaq2mon
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
Novartis NVS obtains FDA approval of atrasentan, a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy ...
AOL2mon
Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
Also Read: FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals ... with previously reported data. This is Novartis’s third U.S. approval for its kidney disease portfolio in the last ...
FiercePharma3mon
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis’ kidney disease troika keeps marching ... with Fierce Pharma ahead of the latest FDA approval. While Fabhalta is the first drug to enter the C3G field, it may soon have company.
FiercePharma2mon
Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics ... safety-related program called REMS. A sans-REMS FDA approval for the drug in IgAN before the end of 2025 was needed to trigger ...
Yahoo Finance3mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Novartis ... This is the third US approval for Fabhalta and its second within the Novartis kidney disease portfolio since August ...
Benzinga.com3mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
The FDA approved Novartis' Fabhalta, making it the first and only treatment for adults with C3 glomerulopathy. Fabhalta showed sustained proteinuria reduction in Phase 3 trials, with effects seen ...
Yahoo Finance3mon
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of ... C3G is a progressive and ultra-rare kidney ...
Yahoo Finance3mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s ... This is the third US approval for Fabhalta and its second within the Novartis kidney disease portfolio since August ...